Browsing: FixedDuration

The phase 1 GO39775 trial (NCT03275103) evaluated cevostamab, a first-in-class FcRH5/CD3 bispecific antibody, as fixed-duration therapy. Investigators administered cevostamab every…

In a conversation with CancerNetwork, Adam D. Cohen, MD, director of Myeloma Immunotherapy and professor of medicine at the Hospital…

The addition of fixed-duration epcoritamab-bysp (Epkinly) to lenalidomide (Revlimid) and rituximab (Rituxan) exhibited superior outcomes vs lenalidomide/rituximab alone across key…